La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Profound Medical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Profound Medical..

Profound Medical (NASDAQ:PROF) Azioni, Catena delle Opzioni

Profound Medical

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Profound Medical Corp

ProFrac Holding Corp. - Class A Common Stock

ProFrac Holding Corp

ProFrac Holding Corp Warrants (09/11/2023)

Professional Diversity Network, Inc. - Common Stock

Professional Diversity Network Inc

Professionally Managed Portfolios Congress Intermediate Bond ETF

Professionally Managed Portfolios Congress Large Cap Growth ETF

Professionally Managed Portfolios Congress SMid Growth ETF

Professionally Managed Portfolios Otter Creek Focus Strategy ETF

Proficient Auto Logistics, Inc. - Common Stock

Proficient Auto Logistics Inc

PROFILE SOLUTIONS INC by Profile Solutions, Inc.

Profile Solutions Inc

Profire Energy Inc

PROFIT PLANNERS MGMT NEW by Profit Planners Management, Inc.

Profit Planners Management Inc

PROFITABLE DEVELOPMENTS by Profitable Developments, Inc.

Profitable Developments Inc

Profound Medical (TSE:PRN) has released an update. Profound Medical has appointed Tom Tamberrino as Chief Commercial Officer to drive the widesprea...

Profound Medical Names New Chief Commercial Officer

In a report released today, Ben Haynor from Lake Street maintained a Buy rating on Profound Medical (PRN – Research Report), with a price target of...

Lake Street Keeps Their Buy Rating on Profound Medical (PRN)

Profound Medical (TSE:PRN) has released an update. Profound Medical is set to release its third quarter financial results on November 7, inviting i...

Profound Medical's Q3 Results and Innovations

Profound Medical (PROF) announced that U.S. Centers for Medicare and Medicaid Services, or CMS, has released its final rule establishing, for the f...

Profound Medical announces CMS established Category 1 CPT for TULSA procedure

Lake Street analyst Ben Haynor maintained a Buy rating on Profound Medical (PRN – Research Report) today and set a price target of $16.50. The comp...

Lake Street Remains a Buy on Profound Medical (PRN)

Profound Medical (TSE:PRN) has released an update. Profound Medical reported a robust 64% revenue growth in Q3 2024, fueled by its innovative TULSA...

Profound Medical Sees Strong Growth with TULSA-PRO®

Reports Q3 revenue $2.83M, consensus $3.01M. "As excited as we were in July that TULSA was poised to start competing with other major prostate trea...

Profound Medical reports Q3 EPS (38c), consensus (30c)

Profound Medical reports Q3 results

Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript

Profound Medical (TSE:PRN) has released an update. Profound Medical Corp., known for its innovative, incision-free medical therapies, is set to pre...

Profound Medical to Present at Stifel Conference

PROF

Press Releases

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

News

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

Earnings

Profound Medical Announces Second Quarter 2024 Financial Results

Health Care

Profound Medical to Participate in Lake Street's Best Ideas Growth Conference

General

Profound Medical's PRO-Talk Live! Event Features the Present and Future of TULSA

Management

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Comments

Profound Medical

Profound Medical (PROF) Opzioni

Profound Medical (NASDAQ:PROF) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO